Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2002-08-15
2008-10-28
Canella, Karen A (Department: 1643)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S024500
Reexamination Certificate
active
07442781
ABSTRACT:
Methods and compositions for the diagnosis, prevention, and treatment of cancer are provided. More particularly, the present invention provides methods and compositions for the diagnosis, prevention, and treatment of cancer through detection and modulation of the expression of TMF/ARA160 and Fer.
REFERENCES:
patent: 3791932 (1974-02-01), Schuurs et al.
patent: 3839153 (1974-10-01), Schuurs et al.
patent: 3850578 (1974-11-01), Mcconnell
patent: 3850752 (1974-11-01), Schuurs et al.
patent: 3853987 (1974-12-01), Dreyer
patent: 3867517 (1975-02-01), Ling
patent: 3879262 (1975-04-01), Schuurs et al.
patent: 3901654 (1975-08-01), Gross
patent: 3935074 (1976-01-01), Rubenstein et al.
patent: 3984533 (1976-10-01), Uzgiris
patent: 3996345 (1976-12-01), Ullman et al.
patent: 4034074 (1977-07-01), Miles
patent: 4098876 (1978-07-01), Piasio et al.
patent: 4666828 (1987-05-01), Gusella
patent: 4683202 (1987-07-01), Mullis
patent: 4801531 (1989-01-01), Frossard
patent: 4879219 (1989-11-01), Wands et al.
patent: 5011771 (1991-04-01), Bellet et al.
patent: 5192659 (1993-03-01), Simons
patent: 5272057 (1993-12-01), Smulson et al.
patent: 5281521 (1994-01-01), Trojanowski
patent: 6426221 (2002-07-01), Ward et al.
patent: WO 01/90337 (2001-11-01), None
patent: WO 02/40717 (2002-05-01), None
Hohjoh et al, FEBS Letters, Jun. 2002, vol. 521, pp. 195-199.
Kurreck (Journal of Biomedicine and Biotechnology, 2006, pp. 1-7).
Tolcher et al (Clinical Cancer Research, 2002, vol 8, pp. 2530-2535).
Cripps et al (Clinical Cancer Research. 2002, 8, pp. 2188-2192).
Marshall et al (Clinical Colorectal Cancer, 2004, vol. 4, pp. 268-274).
Oza et al (Gynecological Oncology, 2003, vol. 89, pp. 129-133).
Verma et al (Nature, 1997, vol. 389, pp. 239-242).
Eck et al (Gene-Based Therapy, In: The Pharmacological Basis of Therapeutics, Goodman and Gilman, Ed.s, 1996, pp. 77-101.
Schultze et al (Trends in Immunology, 2004, vol. 25, pp. 659-664).
Bodey et al, (Anticancer Research, 2000, vol. 20, pp. 2665-2676).
Abstract of Vile et al (Gene Therapy, 2000, vol. 7, pp. 2-8).
Addissson et al (PNAS, vol. 92, pp. 8522-8526.
Garcia, J.A. et al. (1992) Proc.Natl.Acad.Sci.USA 89:9372-9376 “Cloning and chromosomal mapping of a human immunodeficent virus 1 “TATA” element modulatory factor”.
OMIM 601126, Locus ID 7110, GenBank L01042.
Hsiao, et al; (1999) J. Biol. Chem. 274, 22373-22379; “Isolation and Characterization of ARA160 as The First Androgen Receptor N-Terminal—Associated Coactivator In Human Prostate Cells”.
Schwartz, et al., (1998) FEBS Lett. 434, 339-345) “Tyrosine phosphorylation of the TATA element modulatory factor by the FER nuclear tyrosine kinases”.
Pawson, et al. (1989)Mol. Cell. Biol. 9, 5722-5725; “The FER Gene Is Evolutionarily Conserved And Encodes a Widely Expressed Member Of The EPS/FES Protein-Tyrosine Kinase Family”.
Paulson, et al. (1997) Oncogene 14, 641-652 “The Dfer gene of Drosophila melanogaster encodes two membrane-associated proteins that can both transform vertebrate cells”.
Letwin, et al. (1988) Oncogene 3, 621-627 “Novel protein-tyrosine kinase cDNAs related to fps/fes and eph cloned using anti-phosphotyrosine antibody”.
Hao et al; 1989 Mol. Cell. Biol. 9, 1587-1593 Isolation and Sequence Analysis of a Novel Human Tyrosine Kinase Gene.
Hao, et al (1991) Mol. Cell. Biol. 11, 1180-1183 Nuclear and Cytoplasmic Location of the FER Tyrosine Kinase.
Kim, et al. (1998)J. Biol. Chem. 273, 23542-23548 “Growth Factor-dependent Phosphorylation of the Actin-binding Protein Cortactin is mediated by the Cytoplasmic Tyrosine Kinase FER”.
Halachmy, et al. (1997) Oncogene 14, 2871-2880 p94fer facilitates cellular recovery of gamma irradiated pre-T cells.
Rosato, et al (1998) Mol. Cell. Biol. 18 , 5762-5770 “Involvement of the Tyrosine Kinase Fer in Cell Adhesion”.
Priel-Halachmi, et al (2000) J. Biol. Chem. 275, 28902-28910 “FER Kinase Activation of Stat3 is determined by the N-terminal sequence”.
Kim,L and Wong,T.W (1995) Molecular & Cellular Biology “The Cytoplasmic Tyrosine Kinase FER is associated with the Catenin-Like Substrate pp120 and is actived by growth factors”.
Craig, et al. (2001) Mol. Cell Biol. 21, 603-613 “Mice Devoid of Fer Protein-Tyrosine Kinase Activity Are Viable and Fertile but Display Reduced Cortactin Phosphorylation”.
Allard, et al (2000) Mol. Cell Endocrinol. 159, 63-77 “Links between Fe tyrosine Kinase expression levels and prostate cell proliferation”.
Orlovsky, et al. (2000) Biochemistry 39, 11084-11091 “N-Terminal sequences direct the autophosphorylation states of the FER Tyrosine Kinases in Vivo”.
Fischman, et al. (1990) Mol. Cell. Biol. 10, 146-153 “A Murine fer Testis-Specific Transcript (ferT) encodes a truncated Fer Protein”.
Hazan, et al. (1993) Cell Growth Differ. 4, 443-449 “ferT encodes a Meiosis—specific Nuclear Tyrosine Kinase”.
Marx, J. Science (2001) 292: 2231-2233 “Why some Leukemia Cells Resist STI-571”.
Ben-Dor et al . Cell Growth Differ 1999;10:113-29 “Cell cycle-dependent Nuclear accumulation of the p94fer Trosine Kinase is regulated by its NH2 Terminus and is affected by Kinase Domain Integrity and ATP Binding”.
Craig et al. Biol Chem 1999;274:19934-42 “Disruption of coiled-coil domains in Fer Protein-tyrosine Kinase Abolishes Trimrization but not Kinase Activation”.
Arregui et al Cell Biol 2000;149-1263-74 “The Nonreceptor Tyrosine Kinase Fer mediates Cross-talk between N-Cadherin and β1-Integrins”.
Sharp, P. A. Genes Dev 15: 485-490, 2001 RNA interference—2001.
Hannon, G.J. Nature 418: 244-251, 2002 RNA interference.
Fire, A. et al. Nature 391: 806-811, 1998 “Potent and specific genetic interference by double stranded RNA in caenorhabditis elegans”.
Caplen, et al. Proc Natl Acad Sci USA 98, 9742-9747, 2001 “Specific inhibition of gene expression by small double-stranded RNA's in invertebrate and vertebrate systems”.
Elbashir, et al Genes Dev 15:188-200, 2001 “RNA interference is mediated by 21 and 22 nucleotide RNAs”.
Elbashir, et al. Nature 411:494-498, 2001 “Duplexes of 21-nucleotide RNA's mediate RNA interference in cultured mammalian cells”.
Brummelkamp, et al. Science 296:550-553, 2002 “A system for stable Expression of short interfering RNAs in Mammalian cells”.
Tuschl, T. Nature Biotechnology 20:446-448, 2002 “Expanding small RNA interference”.
Paul, et al. . Nature Biotechnology 20:505-508, 2002 “Effective expression of small interfering RNA in human cells”.
Lee, N.S., Dohjima, T., Bauer, G., et al. Nature Biotechnology 20:500-505, 2002 “Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells”.
Tuschl, et al Genes Dev 13: 3191-3197 (1999) “Targeted mRNA degradation by double stranded RNA in vitro”.
The siRNA user guide [http://www.mpibpc.gwdg.de/abteilungen/100/105/sirna.html].
Elbashir SM, Harborth J, Weber K, Tuschl T. Methods Feb;26(2):199-213, (2002).
Nat Genet publication ahead of print; doi:10.1038
g944, 2002 “Efficient delivery of siRNA for inhibition of gene expression in postnatal mice”.
Tartakoff, et al . (1983) J. Cell Biol. 97, 1243-1248 “Lectin-Binding Sites As Markers Of Golgi Subcompartments: Proximal-To-Distal Maturation Of Oligosaccharides”.
Bloom, et al (1989) J. Biol. Chem. 264, 16083-16092 “A novel 58-kDa Protein Associates with the Golgi Apparatus and Microtubes”.
Reaves, et al . (1992) J. Cell Biol. 116, 85-94 Perturbation of the Morphology of the trans-Golgi Network following Brefeldin A treatment : Redistribution of a TGN-specific Integral Membrane Protein TGN38.
Robineau, et al., (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 9913-9918 “Binding site of brefeldin A at the interface between the small G protein ADP-ribosylati
Nir Uri
Pery Erez
Shpungin Sally
Canella Karen A
Hopkins Susanne M.
The Nath Law Group
Urifer Ltd.
Zytcer Ari G.
LandOfFree
Diagnosis, prevention and treatment of cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diagnosis, prevention and treatment of cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diagnosis, prevention and treatment of cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3996997